Imperative Care Appoints COO Daniel Davis as President and Member of Board of Directors

10/30/20:

Imperative Care announced they have appointed Chief Operating Officer Daniel Davis as President and Member of their Board of Directors.

Imperative Care notes Daniel Davis will oversee the growth of the company’s technology portfolio for the treatment of ischemic and hemorrhagic stroke. He will retain his role as COO and join the company’s Board of Directors.

Daniel Davis has more than 20 years of experience in sales, marketing, and business development with both early stage and Fortune 500 medical devices companies, with much of his experience focused on bringing neurovascular innovations to market. Prior to joining Imperative Care in 2019, Mr. Davis served as Chief Commercial Officer and President of North America at Penumbra, Inc., where he led the launch of the first FDA-cleared aspiration system for neurovascular mechanical thrombectomy.

“It’s been a real pleasure working with Daniel and benefiting from his steadfast commitment to elevating stroke care which has enabled him to make significant contributions from the outset of his time at Imperative Care. I am thrilled to see his leadership grow within the organization as he now oversees our efforts to bring much-needed innovation to the field of stroke,” said Fred Khosravi, Imperative Care’s founding Chairman and CEO.

“Many of us at Imperative Care are driven by our personal connection to stroke and the pursuit of better, more streamlined care for stroke patients and their families,” said Mr. Davis. “Imperative Care’s resolute dedication to innovation across the continuum of stroke care has been inspirational to me. I am convinced that this will position the company to revolutionize the stroke space and excited to continue leading the company alongside Fred and our seasoned leadership team.”

Imperative Care is currently commercializing two platforms that offer physicians new capabilities to treat their patients, the industry’s first Large Distal Platform™ (LDP™) access technology, including TracStar LDP™, and unparalleled thrombectomy technology, the Zoom™ Stroke Solution. The company is also developing a pipeline of additional stroke-care innovations.

Stroke remains a largely unaddressed problem that affects over 800,000 Americans each year.1 Treatment options have significantly improved over the last decade, but the need for improved effectiveness and efficiency remains. Imperative Care aims to invest significantly in clinical evidence to advance the standard of care for stroke patients worldwide.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version